Preclinical Models for Novel Drug Combination in Advanced Ovarian Cancer
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".
Deadline for manuscript submissions: closed (30 November 2024) | Viewed by 151
Special Issue Editor
Special Issue Information
Dear Colleagues,
Advanced ovarian cancer is predominantly fatal and imposes a significant health burden on patients’ quality of life. Despite notable advancements in drug discovery, options for drug treatment at advanced stages remain limited, albeit viable clinical trials have emerged. The PARP inhibitor family stands out as a well-recognized treatment for patients exhibiting abnormal BRCAness functions. Additionally, antiangiogenic drugs have shown promise in enhancing the efficacy of conventional platinum and Texan regimens. However, the failure rate of this combination regimen, involving both PARP inhibitors and antiangiogenic blockers, remains high. Such ineffectiveness underscores the challenges inherent in the ongoing drug discovery pipeline for ovarian cancer. Hence, this Special Issue on ovarian cancer will primarily focus on novel drug combinations validated in preclinical models. The potential of these novel combinations presents an exciting avenue, potentially leading to the discovery of potent drug combination therapies that can undergo clinical trials. Furthermore, this Special Issue will delve into combinations of repurposed medications and natural products, which hold promise as viable options for testing in preclinical models.
Dr. Kenny Chitcholtan
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- ovarian cancer
- drug treatment
- clinical trials
- PARP inhibitors
- 3D cell models
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
